You'll want to sign them up for a clinical trial. Only CAR-T cell therapies that are FDA approved are for leukemias. [ and as a commentator points out, for lymphomas, I had always thought lymphomas were a subset of leukemia. mea culpa ]
Multiple myeloma has Carvykti and Abecma
https://www.cancer.gov/sites/g/files/xnrzdm211/files/styles/...
With respect to institutions:
East coast: Sloan Kettering in NYC and Dana Farber in Boston
Middle America: MD Anderson in Houston
West coast: City of Hope and UCLA in Los Angeles.
Basically we got nothing from them.
Not sure what my point is other than if you’re getting a second opinion, discuss how the provider will integrate their assessment with the existing treatment plan. And at the end of the day it’s the doctors and nurses you get that make the difference in your care, not the building.
She passed in 2020, just two years after diagnosis.
https://en.wikipedia.org/wiki/Axicabtagene_ciloleucel
> On 1 April 2022, the FDA approved axicabtagene ciloleucel for adults with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within twelve months of first-line chemoimmunotherapy.
I was in a clinical trial, though, but that was to determine the effectiveness of Anakinra in preventing serious side-effects; in my case, I only got a few mild fevers, which is the biochemical equivalent of winning the lottery, in a lottery where losers end up comatose and intubated.
Details on this is part of the trial listing which is usually on https://clinicaltrials.gov/